CONTACT: KURT E. HEIAR
President & Chief Executive Office
2501 Crosspark Road
CONTACT: TOM BAUER
109 Technology Innovation Center
Oakdale Research Park
Iowa City IA 52242
EnzyMed, Inc. and UI announce five-year research collaboration
CORALVILLE, Iowa -- EnzyMed, Inc. and the University of Iowa today,
Thursday, May 28, announced a five-year collaboration agreement that will
match research efforts at the UI with complementary pharmaceutical technology
at EnzyMed. EnzyMed specializes in the discovery and development of pharmaceutical
and agrochemical compounds.
Under the agreement, UI researchers working on new compounds or on biological
targets for drugs may collaborate with EnzyMed. In the latter case, EnzyMed
will supply an array of chemical compounds to be tested for their activity
against and their affinity for the targets identified by the UI. In February,
EnzyMed reached an agreement with Iowa State University that is similar
to the UI agreement.
EnzyMed's proprietary BIOACTIVTM technology enables the company to generate
a large number of chemically related compounds or "libraries."
If a target identified at the UI leads to identification of a marketable
new drug, the UI and EnzyMed will share in the benefits of commercialization.
"Given the excellent faculty and research staff at the University
of Iowa, we are confident that this collaboration will lead to interesting
new compounds for commercialization," said Marti Fleming, EnzyMed
director of business development . "The agreement adds structure
to the relationship EnzyMed has enjoyed with the university since our founding
in 1994," added Kurt Heiar, EnzyMed president and CEO.
"We are hopeful that this collaboration will lead to the development
of new medicines," said David J. Skorton, UI vice president for research.
"First and foremost, such an outcome would benefit the public, but
it would also benefit the University of Iowa and EnzyMed. We have created
the Technology Innovation Center (a business incubator) and the Oakdale
Research Park so that we can enable this sort of mutually beneficial relationship."
EnzyMed is affiliated with the Technology Innovation Center on the UI
Oakdale Research Campus in Coralville. It is a growing company whose technology
platform originated from research at the University of Iowa and the University
of California, Berkeley.
EnzyMed, Inc specializes in the discovery and optimization of pharmaceutical
and agrochemical compounds utilizing a proprietary combinatorial biocatalysis
platform. EnzyMed is the first company to integrate iterative enzymatic
and microbial reactions with selected chemical synthesis on an automated
platform for application to drug optimization. EnzyMed's unique technology
has proven itself applicable to many types of therapeutics including small
molecules, natural products, and complex synthetic lead compounds and is
focused on accelerating lead optimization timeliness. The company currently
has a number of collaborations with pharmaceutical partners worldwide in
lead optimization, lead generation, and joint discovery areas.